Sugi Predict

Sugi Predict / Compounds / SCHEMBL898459

SCHEMBL898459

SCHEMBL898459

Cc1ccc(S(=O)(=O)N(CCI)CCI)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLA P06280 1/20 0.56
▸ CNR2 P34972 6/20 0.51
▸ MAPT P10636 1/20 0.48
▸ MCOLN3 Q8TDD5 1/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ LMNA P02545 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ C5AR1 P21730 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ AGER Q15109 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ CA12 O43570 2/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ CA2 P00918 1/20 0.45
▸ SLC22A6 Q4U2R8 1/20 0.45
▸ SLC22A8 Q8TCC7 1/20 0.45
▸ ABCC2 Q92887 1/20 0.45
▸ SLC22A12 Q96S37 1/20 0.45
▸ UGT1A7 Q9HAW7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16884872 0.83 MAPT (0.52) GLACNR2MAPTMCOLN3SMN1; SMN2
Ditolamide SCHEMBL2110790 0.82 CA9 (0.64) GLACNR2SMN1; SMN2LMNAHTT
SCHEMBL398044 0.81 CNR2 (0.57) GLACNR2MAPTMCOLN3SMN1; SMN2
SCHEMBL8634136 0.81 GLA (0.56) GLACNR2MAPTMCOLN3SMN1; SMN2
SCHEMBL218536 0.81 SMN1; SMN2 (0.68) GLACNR2MAPTMCOLN3SMN1; SMN2
SCHEMBL2362509 0.81 GLA (0.56) GLACNR2MAPTMCOLN3SMN1; SMN2
SCHEMBL3694171 0.79 CNR2 (0.58) GLACNR2MAPTSMN1; SMN2LMNA
SCHEMBL15177296 0.79 SMN1; SMN2 (0.66) GLACNR2MAPTMCOLN3SMN1; SMN2
SCHEMBL11711049 0.79 SMN1; SMN2 (0.56) GLACNR2MAPTMCOLN3SMN1; SMN2
SCHEMBL8192690 0.79 SMN1; SMN2 (0.66) GLACNR2MAPTMCOLN3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
EP-3613729-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-02-26 — — EP disclosed
EP-3345903-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2019-10-09 — — EP disclosed
EP-3345903-A1 TETRACYCLIC COMPOUNDS Chugai Seiyaku Kabushiki Kaisha (JP) 2018-07-11 — — EP disclosed
EP-2975024-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2018-03-28 — — EP disclosed
WO-2018051109-A1 NOVEL CYTOTOXIC AGENTS AND CONJUGATES THEREOF POLYTHERICS LIMITED (GB) 2018-03-22 — — WO disclosed
US-20160340308-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-24 — — US disclosed
US-9440922-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-09-13 — — US disclosed
EP-2441753-B1 TETRACYCLIC COMPOUND CHUGAI PHARMACEUTICAL CO LTD (JP) 2016-03-30 — — EP disclosed
US-20030204089-A1 Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine COSSEMENT ERIC (BE) 2003-10-30 — — US disclosed
US-20030105113-A1 Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine COSSEMENT ERIC (BE) 2003-06-05 — — US disclosed
US-20030105112-A1 Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine COSSEMENT ERIC (BE) 2003-06-05 — — US disclosed
US-6436942-B1 ADMINISTERING THE ANTIHISTAMINE, CETIRIZINE, PRODUCED FROM THIS INTERMEDIATE OF HIGH OPTICAL PURITY UCB, S.A. (BE) 2002-08-20 — — US disclosed
EP-0617028-B1 Enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl] piperazine UCB SA (BE) 2000-06-14 — — EP disclosed
EP-0955295-A1 Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines UCB, S.A. (BE) 1999-11-10 — — EP disclosed
US-5792770-A ADMINISTERING AS SEDATIVE, TRANQUILIZER, ANXIOLYTIC AGENT U C B S.A. (BE) 1998-08-11 — — US disclosed
US-5703082-A ANTIHISTAMINE; TRANQUILIZERS U C B S.A. (BE) 1997-12-30 — — US disclosed
US-5478941-A Useful in treatment of asthma, allergies, inflammation and anxiety; antihistaminic activity U C B, S.A. (BE) 1995-12-26 — — US disclosed
EP-0617028-A1 Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine U C B, S.A. (BE) 1994-09-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 GLA 1496/4885CNR2 2980/4885MAPT 68/4885
US-20030105113-A1 Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine RPLP1, QDPR, PRLHR GLA 4002/4885CNR2 386/4885MAPT 2993/4885
US-20030204089-A1 Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine RPLP1, QDPR, PRLHR GLA 4002/4885CNR2 386/4885MAPT 2993/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 GLA 1496/4885CNR2 2980/4885MAPT 68/4885
US-20160340308-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 GLA 1496/4885CNR2 2980/4885MAPT 68/4885
US-20030105112-A1 Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine RPLP1, QDPR, RPLP2 GLA 3956/4885CNR2 414/4885MAPT 3156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.